CN111297869A - 一种用于治疗早泄和勃起功能障碍的复方制剂 - Google Patents
一种用于治疗早泄和勃起功能障碍的复方制剂 Download PDFInfo
- Publication number
- CN111297869A CN111297869A CN202010329426.7A CN202010329426A CN111297869A CN 111297869 A CN111297869 A CN 111297869A CN 202010329426 A CN202010329426 A CN 202010329426A CN 111297869 A CN111297869 A CN 111297869A
- Authority
- CN
- China
- Prior art keywords
- erectile dysfunction
- treating
- premature ejaculation
- paroxetine hydrochloride
- sildenafil citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001881 impotence Diseases 0.000 title claims abstract description 31
- 208000010228 Erectile Dysfunction Diseases 0.000 title claims abstract description 28
- 206010036596 premature ejaculation Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 title claims abstract description 9
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960002639 sildenafil citrate Drugs 0.000 claims abstract description 15
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960005183 paroxetine hydrochloride Drugs 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 229940009505 paroxetine hydrochloride 20 mg Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 7
- 208000019901 Anxiety disease Diseases 0.000 abstract description 5
- 230000036506 anxiety Effects 0.000 abstract description 5
- 230000036651 mood Effects 0.000 abstract description 3
- 230000001568 sexual effect Effects 0.000 description 9
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 210000003899 penis Anatomy 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 4
- 229960005217 dapoxetine Drugs 0.000 description 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 3
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 101150098694 PDE5A gene Proteins 0.000 description 2
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 2
- 210000005226 corpus cavernosum Anatomy 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960000835 tadalafil Drugs 0.000 description 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229960000307 avanafil Drugs 0.000 description 1
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于治疗早泄和勃起功能障碍的复方制剂，由以下重量的药物组成：枸橼酸西地那非40‑120mg，盐酸帕罗西汀10‑50mg。有益效果在于：枸橼酸西地那非治疗勃起功能障碍，盐酸帕罗西汀解除患者焦虑抑郁的情绪，从而提高对勃起功能障碍的治疗效果；盐酸帕罗西汀治疗早泄，枸橼酸西地那非治疗因盐酸帕罗西汀产生的勃起功能障碍的副作用，从而提高了早泄治疗的有效率。
Description
技术领域
本发明涉及泌尿科学技术领域，特别是涉及一种用于治疗早泄和勃起功能障碍的复方制剂。
背景技术
早泄是最常见的射精功能障碍，以性交之始即行排精，甚至性交前即泄精，不能进行正常性生活为主要表现，发病率占成年男子的1/3以上。早泄的定义尚有争议，通常以男性的射精潜伏期或女性在性交中达到性高潮的频度来评价，如以男性在性交时失去控制射精的能力，则阴茎插入阴道之前或刚插入即射精为标准；或以女性在性交中达到性高潮的频度少于50％为标准来定义早泄，但这些都未被普遍接受。因为男性的射精潜伏期受年龄、禁欲时间长短、身体状况、情绪心理等因素影响，女性性高潮的发生频度亦受身体状态、情感变化、周围环境等因素影响。另外，射精潜伏期时间的长短也有个体差异，一般认为，健康男性在阴茎插入阴道2-6分钟后发生射精，即为正常。
勃起功能障碍是最常见的一种男性勃起功能障碍，指阴茎持续不能达到或维持足够的勃起以完成满意满意性生活，病程3个月以上。既往将男子“性无能”泛称为“阳萎”，其科学界定不确切，并且带有歧视性贬义。直到1992年，美国国立卫生院经有关专家讨论，决定用勃起功能障碍(ED)一词代替阳萎，并将阴茎勃起功能障碍定义为：阴茎持续不能达到和(或)维持足够的勃起以获得满意的性生活。
目前治疗勃起功能障碍(ED)与早泄(PE)国内的药物有中成药，包括金匮肾气丸、六味地黄丸等，疗效有待商确。治疗勃起功能障碍的西药有枸橼酸西地那非、酚妥拉明、他达拉非等，治疗早泄的药除中药外仅有盐酸达帕西汀(进口)。目前针对勃起功能障碍和早泄的双效治疗国内没有，国外的复方制剂有阿伐那非+达帕西汀、枸橼酸西地那非+达帕西汀、他达拉非+达帕西汀。
由于ED患者多数伴有紧张、压力、抑郁、焦虑和夫妻感情不和等精神心理因素，有时被临床医生忽视，或者患者拒绝同时服用抗抑郁药，使得治疗勃起功能的药疗效受到影响。
发明内容
本发明的目的就在于为了解决上述问题而提供一种用于治疗早泄和勃起功能障碍的复方制剂。
本发明通过以下技术方案来实现上述目的：
一种用于治疗早泄和勃起功能障碍的复方制剂，由以下重量的药物组成：枸橼酸西地那非40-120mg，盐酸帕罗西汀10-50mg。
进一步的，由以下重量的药物组成：枸橼酸西地那非50mg，盐酸帕罗西汀20mg。
本发明的有益效果在于：枸橼酸西地那非治疗勃起功能障碍，盐酸帕罗西汀解除患者焦虑抑郁的情绪，从而提高对勃起功能障碍的治疗效果；盐酸帕罗西汀治疗早泄，枸橼酸西地那非治疗因盐酸帕罗西汀产生的勃起功能障碍的副作用，从而提高了早泄治疗的有效率。
具体实施方式
下面将结合实施例对本发明的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
一种用于治疗早泄和勃起功能障碍的复方制剂，由以下重量的药物组成：枸橼酸西地那非50mg，盐酸帕罗西汀20mg。
治疗勃起功能障碍时，枸橼酸西地那非为主要作用，枸橼酸西地那非是高度选择性磷酸二酯酶5(PDE5)抑制剂，PDE5在阴茎海绵体中高度表达，而在其它组织中(包括血小板、血管和内脏平滑肌、骨骼肌)，表达低下，西地那非通过选择性抑制PDE5，增强一氧化氮(NO)－cGMP途径，升高cGMP水平而导致阴茎海绵体平滑肌松弛，使勃起功能障碍患者对性刺激产生自然的勃起反应，此时盐酸帕罗西汀解除患者焦虑抑郁的情绪，从而与西地那非产生协同作用。
治疗早泄时，所述盐酸帕罗西汀为主要作用，盐酸帕罗西汀是一种选择性5-羟色胺再摄取抑制剂(SSRI)，口服后能选择抑制5-HT转运体，促使受体去敏感化，阻断突触前膜再摄取5-HT，提高突触间隙内5-HT浓度，延长5-HT作用时间，发挥着显著的抗焦虑、抗抑郁作用，而盐酸帕罗西汀起到延长射精时间的同时，会引起患者勃起功能障碍，此时枸橼酸西地那非用于治疗该副作用，进而产生协同作用。
使用方法：性生活前1.5—2小时服用；体重较重的人，适当增加半片到1片，最多每天一次。
禁忌：禁止与胆胺氧化酶抑制剂合用；服用任何剂型硝酸酯的患者，无论是规律服用或间断服用，均不可服用。
以上显示和描述了本发明的基本原理、主要特征和优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。
Claims (2)
1.一种用于治疗早泄和勃起功能障碍的复方制剂，其特征在于：由以下重量的药物组成：枸橼酸西地那非40-120mg，盐酸帕罗西汀10-50mg。
2.根据权利要求1所述的一种用于治疗早泄和勃起功能障碍的复方制剂，其特征在于：由以下重量的药物组成：枸橼酸西地那非50mg，盐酸帕罗西汀20mg。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010329426.7A CN111297869A (zh) | 2020-04-23 | 2020-04-23 | 一种用于治疗早泄和勃起功能障碍的复方制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010329426.7A CN111297869A (zh) | 2020-04-23 | 2020-04-23 | 一种用于治疗早泄和勃起功能障碍的复方制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111297869A true CN111297869A (zh) | 2020-06-19 |
Family
ID=71154200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010329426.7A Pending CN111297869A (zh) | 2020-04-23 | 2020-04-23 | 一种用于治疗早泄和勃起功能障碍的复方制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111297869A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791090A (zh) * | 2021-03-25 | 2021-05-14 | 河北雄安日出海上生物科技有限公司 | 一种用于治疗勃起功能障碍及早泄的组合片 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1474692A (zh) * | 2000-11-20 | 2004-02-11 | 早泄的治疗 | |
| CN101559055A (zh) * | 2008-04-14 | 2009-10-21 | 北京卓越同创药物研究院 | 一种药物的用途 |
| CN102309608A (zh) * | 2011-10-10 | 2012-01-11 | 徐究竟 | 治疗男性功能性早泄的药物及其制备工艺 |
| CN110214007A (zh) * | 2017-06-14 | 2019-09-06 | 江苏恒瑞医药股份有限公司 | 一种控释药物组合物及其制备方法 |
-
2020
- 2020-04-23 CN CN202010329426.7A patent/CN111297869A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1474692A (zh) * | 2000-11-20 | 2004-02-11 | 早泄的治疗 | |
| CN101559055A (zh) * | 2008-04-14 | 2009-10-21 | 北京卓越同创药物研究院 | 一种药物的用途 |
| CN102309608A (zh) * | 2011-10-10 | 2012-01-11 | 徐究竟 | 治疗男性功能性早泄的药物及其制备工艺 |
| CN110214007A (zh) * | 2017-06-14 | 2019-09-06 | 江苏恒瑞医药股份有限公司 | 一种控释药物组合物及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 操作亮，等: "西地那非联合多沙唑嗪治疗早泄的临床观察", 《中国男科学杂志》 * |
| 薛，等: "早泄的研究进展", 《中华男科学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791090A (zh) * | 2021-03-25 | 2021-05-14 | 河北雄安日出海上生物科技有限公司 | 一种用于治疗勃起功能障碍及早泄的组合片 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cantor et al. | Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin | |
| Jannini et al. | Correlation between ejaculatory and erectile dysfunction | |
| AU758888B2 (en) | Natural composition and method for the treatment of sexual dysfunction | |
| US6338862B1 (en) | Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors | |
| AU2006312373B2 (en) | Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction | |
| CN111297869A (zh) | 一种用于治疗早泄和勃起功能障碍的复方制剂 | |
| Nimesh et al. | Erectile Dysfunction: An Update | |
| Athanasiadis | Premature ejaculation: is it a biogenic or a psychogenic disorder? | |
| Haugen | Double blind cross-over study of a new appetite suppressant AN 448 | |
| Bennett | Sexual dysfunction: behavioral, medical, and surgical treatment | |
| Ismail et al. | Recurrent epistaxis after treatment with tadalafil (Cialis) | |
| McGuire | Sexual health: management of erectile dysfunction. | |
| Andhale et al. | Stuttering priapism in a case of Sickle Cell Disease–A case report | |
| Jannini et al. | Couple therapy for premature ejaculation | |
| McGuire | Dealing with reality: Sexual health: Management of erectile dysfunction | |
| WO2015139301A1 (zh) | 一种滋阴补肾、改善性功能的油类混合物 | |
| Nagaraj et al. | Etiology and management of sexual dysfunction | |
| RU2228754C1 (ru) | Способ лечения и профилактики эректильной дисфункции | |
| KAMAR et al. | " Role of Panchakarma therapy in the management of Pakshaghata" A Case Study. | |
| Campbell | Male sexual dysfunction: continuing medical education | |
| Hakkandi et al. | A comparative clinical study on Brihmana effect of Ashwagandhaadya Ghrita Snehanapana and Matra Basti in Karshya wsr to Under Weight | |
| Payne | Erectile dysfunction: A historical review | |
| JP5587671B2 (ja) | Ｐｄｅ５阻害剤と反鼻とを含有する医薬組成物 | |
| RU2031652C1 (ru) | Способ лечения половых расстройств при хроническом простатите | |
| CN103340978A (zh) | 一种治疗尿频、尿急的中西组合药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200619 |